TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) produced a 22.5% rally since recording the worst price of $2.00. Thanks to the latest -15.52% decrease, it now trades at $2.45. Throughout the trading on 02/12/2018, the share price floated between $2.35 and $2.9. This company shares are 312.24% off its target price of $10.1 and the current market capitalization stands at $42.92M. The recent change has given its price a -18.58% deficit over SMA 50 and -47.82% deficit over its 52-week high. The stock witnessed -23.44% declines, -16.95% declines and 8.89% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TCON’s volatility during a week at 11.81% and during a month it has been found around 9.37%.TRACON Pharmaceuticals, Inc. (TCON) Top Holders
Institutional investors currently hold around $17 million or 50% in TCON stock. Look at its top three institutional owners. Nea Management Company, Llc owns $8 million in TRACON Pharmaceuticals, Inc., which represents roughly 18.64% of the company’s market cap and approximately 47.07% of the institutional ownership. Similar statistics are true for the second largest owner, 683 Capital Management, Llc, which owns 995,000 shares of the stock are valued at $2.89 million. The third largest holder is Eventide Asset Management, Llc, which currently holds $2.61 million worth of this stock and that ownership represents nearly 6.08% of its market capitalization.
At the end of 12/31/2017 reporting period, 14 institutional holders increased their position in TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) by some 1,140,286 shares, 9 decreased positions by 582,233 and 10 held positions by 4,254,241. That puts total institutional holdings at 5,976,760 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 1,053,452 shares while 5 institutional investors sold out their entire positions totaling 530,153 shares.TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Insider Trades
Multiple company employees have indulged in significant insider trading. TRACON Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Larue William R has sold 2,500 shares of TRACON Pharmaceuticals, Inc. (TCON) in trading session dated Jun. 02, 2017. These shares are worth $6,725 and were traded at $2.69 each. The SEC filing shows that Barrett M James performed a purchase of 869,565 shares. The 10% Owner added these shares by way of transaction on Nov. 29, 2016. The company’s shares were assimilated at $5.75 per share worth to an investment of some $4,999,999 on account of Barrett M James.
10% Owner, Barris Peter J, purchased 869,565 common shares of TRACON Pharmaceuticals, Inc. (TCON) in the open market. In a transaction dated Nov. 29, 2016, the shares were bought at an average price of $5.75, giving away a sum of $4,999,999. After this purchase, 2,758,039 common shares of TCON are directly owned by the insider, with total stake valued at $6,757,196.
In the transaction dated Nov. 29, 2016, the great number of shares acquired came courtesy the 10% Owner; Baskett Forest added a total of 869,565 shares at an average price of $5.75, amounting to approximately $4,999,999. The insider now directly owns 2,758,039 shares worth $6,757,196.TRACON Pharmaceuticals, Inc. (TCON) Analyst Guide
Several analysts have released their opinion on TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation.